About PolyPid
PolyPid is a company based in Petah Tikva (Israel) founded in 2008. PolyPid has raised $96.71 million across 10 funding rounds from investors including Xenia Venture Capital, Shavit Capital and Aurum Ventures. The company has 61 employees as of December 31, 2024. PolyPid offers products and services including PLEX Platform, D-PLEX 100, and D-PLEX 1000. PolyPid operates in a competitive market with competitors including PanTher Therapeutics, Zyl Therapeutics, Santen Pharmaceuticals, Lexaria Bioscience and LabInCube, among others.
- Headquarter Petah Tikva, Israel
- Employees 61 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Polypid Ltd.
-
Annual Revenue
Not available
-
Net Profit
-$29.02 M (USD)-21.61as on Dec 31, 2024
-
EBITDA
-$26.41 M (USD)-25.48as on Dec 31, 2024
-
Total Equity Funding
$96.71 M (USD)
in 10 rounds
-
Latest Funding Round
$26.69 M (USD), Post-IPO
Jun 16, 2025
-
Investors
Xenia Venture Capital
& 3 more
-
Employee Count
61
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of PolyPid
PolyPid is a publicly listed company on the NASDAQ with ticker symbol PYPD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of PolyPid
PolyPid offers a comprehensive portfolio of products and services, including PLEX Platform, D-PLEX 100, and D-PLEX 1000.
Enables localized, controlled release of medications for surgical use.
Prevents surgical site infections via extended antibiotic delivery.
Targets bone-related infections with prolonged drug release.
People of PolyPid
Unlock access to complete
Unlock access to complete
Funding Insights of PolyPid
PolyPid has successfully raised a total of $96.71M across 10 strategic funding rounds. The most recent funding activity was a Post-IPO round of $26.69 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PolyPid
PolyPid has secured backing from 4 investors, including venture fund and institutional investors. Prominent investors backing the company include Xenia Venture Capital, Shavit Capital and Aurum Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in Israel are managed by Shavit Capital.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Early-stage centric life sciences and tech focused VC firm investing primarily in Israel and the US
|
Locked | Locked | Locked |
Investor details for PolyPid
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PolyPid
Investment portfolio details for PolyPid
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PolyPid
Detailed financials for PolyPid
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Polypid Comparisons
Peer comparison for PolyPid
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PolyPid
PolyPid operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PanTher Therapeutics, Zyl Therapeutics, Santen Pharmaceuticals, Lexaria Bioscience and LabInCube, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Drug delivery systems for inoperable solid tumors are developed.
|
|
| Locked | Locked | Locked |
Hydrogel-derived nanoparticles for topical drug delivery are developed.
|
|
| Locked | Locked | Locked |
Pharmaceutical products for ophthalmology and rheumatology diseases are manufactured.
|
|
| Locked | Locked | Locked |
Patented drug delivery technology is developed for bioactive molecules.
|
|
| Locked | Locked | Locked |
Drug-releasing medical devices and medicines are developed with InCube technology.
|
Detailed competitors of PolyPid
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Polypid
Complete news archive for PolyPid
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PolyPid
PolyPid was founded in 2008 and raised its 1st funding round 4 years after it was founded.
PolyPid is headquartered in Petah Tikva, Israel. It is registered at Petah Tikva, Central District, Israel.
PolyPid is a funded company, having raised a total of $96.71M across 10 funding rounds to date.
As of Dec 31, 2024, the latest employee count at PolyPid is 61.
PolyPid has developed a technology platform (PLEX-Polymer-Lipid Encapsulation matriX) that enables a controlled and prolonged release of any active pharmaceutical ingredients (API). Its technology combines polymers and lipids, enabling small-and-large API entrapment in degradation and hydration protected environments, regardless of their chemical or physical characteristics. It allows the release of the API from the reservoir at pre-determined rates of up to several months, with a constant release rate. Its pipeline includes D-PLEXantibiotic drug reservoir designed to be implanted during surgery to prevent or treat surgical site infections (SSIs)), Bonypid-1000 (an antibiotic designed for bone related infections applications) and Bonypid-500 (an antibiotic eluting bone graft substitute intended to fill, augment or reconstruct periodontal or oralmaxillofacial defects while protecting from infections).
PolyPid's top competitors include PanTher Therapeutics, Lexaria Bioscience and Santen Pharmaceuticals.
PolyPid offers PLEX Platform, D-PLEX 100, and D-PLEX 1000.
Yes, PolyPid is publicly traded on NASDAQ under the ticker symbol PYPD.
PolyPid has 4 investors. Key investors include Xenia Venture Capital, Shavit Capital, Aurum Ventures, and Yellin Lapidot.
The ticker symbol of PolyPid is PYPD on NASDAQ.